Bandi Parthasaradhi Reddy – Chairman & Managing Director, Hetero…
Since the company’s foundation in 1993, Hetero has clearly come a long way. What were the key success factors at that time, which laid the groundwork of a successful company?…
Address: HETERO DRUGS LIMITED, 7-2-A2, HETERO CORPORATE, INDUSTRIAL ESTATES. SANATH NAGAR, HYDERABAD – 500 018. A.P. INDIA
,India
Tel: +91 40 23704923
Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs.
Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization. Hetero is a leading international supplier with a rich portfolio of over 200 products from wide range of therapeutic categories both in active pharmaceutical ingredients and finished dosages.
Hetero’s manufacturing facilities are cGMP compliant meeting global standards in terms of infrastructure and systems. Majority of them are approved by the various regulatory authorities of USFDA, WHO-Geneva, Australian TGA, Spanish agency of medicines & health care products, ANVISA-Brazil, IDA-Netherlands etc.,
With full-fledged marketing capabilities, the company has been able to market its products in over 138 countries across the globe.
APIs
Hetero is one of the largest manufacturer and supplier of Active Pharmaceutical Ingredients (API’s) catering to the ever increasing requirements of the global pharmaceutical market.
The infrastructure available with Hetero for manufacturing of Active Pharmaceutical Ingredients and the intermediate chemicals is one of the best, with State-of-the- Art facilities designed to meet the global standards and cGMPs.
With 11 API manufacturing facilities in operation, Hetero has been able to manufacture more than 200 APIs, and supply to different markets. 6 of the API facilities are approved by USFDA, TGA, EU, PMDA, KFDA and WHO.
Hetero is a trusted supplier of several APIs in wide range of therapeutic categories and the largest supplier of complete range in Antiretroviral products.
Hetero also has dedicated facility for manufacturing of Oncology products.
FINISHED DOSAGES
Hetero has world-class facilities for manufacturing wide range of finished dosages.
As a leading innovation-driven corporation, Hetero is developing a growing portfolio of pharmaceutical products to meet some of the world’s most urgent medical needs. Today Hetero is manufacturing product portfolio of over 200 products in major therapeutic areas, with an emphasis on antiretroviral, gastro-intestinal, cardiovascular, antidepressants/antipsychotics, antidiabetics, pain management, anti-infectives, dermatology and oncology. Hetero has
Four finished dosage manufacturing facilities, out of which two are USFDA approved facilities.
Dedicated Oncology facility
Offers
Injectables
Solid/Liquid oral dosages
Ointments
Soft gelatine capsules
Inhalers
INTERMEDIATE CHEMICALS
For information on intermediate chemicals please contact:
uma@heterodrugs.com
contact@heterodrugs.com
CRAMS
Hetero initiated customer-centric division that will provide Custom Research And Manufacturing Services (CRAMS) for large, mid-sized and emerging biotech and pharmaceutical entities globally.
Hetero will partner with these companies and cultivate opportunities to research, manufacture and develop compounds across the entire drug life cycle. This division will deliver fully-consolidated or customized manufacturing solutions for APIs, intermediate chemicals, pre-formulations and formulations across each stage of the pharmaceutical life cycle. Hetero provides premium solutions for product life cycle management including life cycle extensions and line extensions.
BIOTECHNOLOGY
Hetero is focusing on the development and manufacturing of bio-generics for domestic and international markets.
Product Pipeline
Five biosimilars are in the various stages of development. Two products are expected to be commercialized in India for oncology and nephrology indications by 2011-12.
DRUG DISCOVERY
Hetero started discovery research with the focus on developing NCEs in selected therapeutic areas. Scientists at Drug Discovery Division are working on the following projects :
ANTI-HIV Research
ANTI-HCV Research
Diabetes Research
Our business strategy is to out licence early stage discovery molecules and to explore early stage discovery collaborations to maximize the potential of our discovery projects.
Since the company’s foundation in 1993, Hetero has clearly come a long way. What were the key success factors at that time, which laid the groundwork of a successful company?…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in…
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions for Indian pharma manufacturers and could lead to global shortages. Shortages and Price…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the coronavirus, to regulatory reform, the spike in USFDA warning letters…
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia…
The state of Gujarat proudly stands as India’s main pharmaceutical hub, accounting for over 33 percent of the country’s pharmaceutical turnover and 28 percent of its pharmaceutical exports. Given the…
Unlike many of his pharma peers, Vivek Sharma worked in operations and finance for two decades before joining the life sciences industry as head of Piramal Pharma Solutions (PPS) in…
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both…
Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India’s ambitious healthcare insurance scheme, “Modicare” and delves into some of its critical challenges and associated…
Dilip Shah, the Secretary-General of the Indian Pharmaceutical Alliance advocates for a stronger and more empowered regulator in India if the country is to build public confidence in its pharma output…
Indian pharma companies provide affordable generic drugs to patients in almost all countries across the globe, hence the reason India has been dubbed ‘ the pharmacy to the world.’ Furthermore,…
Although most industry observers expect that Indian pharma exports to the US will pick up again in the coming years, Indian companies have – in the meantime – been rapidly…
In a context where even well-established, multi-billion-dollar domestic companies have received warning letters from the US FDA, quality compliance has clearly become strategically important across all layers of Indian organizations,…
See our Cookie Privacy Policy Here
